Cetera Investment Advisers Grows Stock Position in GSK PLC Sponsored ADR (NYSE:GSK)

Cetera Investment Advisers increased its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 286,547 shares of the pharmaceutical company’s stock after buying an additional 23,948 shares during the quarter. Cetera Investment Advisers’ holdings in GSK were worth $11,101,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its position in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares during the period. Voloridge Investment Management LLC raised its position in GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company’s stock valued at $73,222,000 after purchasing an additional 2,016,795 shares during the period. Bridgewater Associates LP raised its position in GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company’s stock valued at $76,017,000 after purchasing an additional 1,281,855 shares during the period. Woodline Partners LP purchased a new stake in GSK in the fourth quarter valued at approximately $36,665,000. Finally, Miller Howard Investments Inc. NY raised its position in GSK by 138.4% in the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company’s stock valued at $63,797,000 after purchasing an additional 955,891 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE:GSK opened at $39.00 on Thursday. The company has a fifty day simple moving average of $39.02 and a two-hundred day simple moving average of $37.60. The company has a market cap of $79.62 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 1.53 and a beta of 0.50. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.43 earnings per share. As a group, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were paid a $0.4216 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.32%. GSK’s payout ratio is 88.14%.

Analyst Ratings Changes

GSK has been the topic of a number of research analyst reports. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price on the stock. Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a research report on Saturday, July 26th. Berenberg Bank reissued a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res raised GSK to a “strong sell” rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, GSK currently has an average rating of “Hold” and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.